MONTEGO BAY, Jamaica, Feb.
22, 2024 – PRESS RELEASE – Pure Jamaican and its GMP-certified, licensed pharma manufacturer Seven-10 Pharmaceuticals are elevating
Jamaica's role in the global cannabis supply chain by legally exporting
proprietary pharmaceutical products with cannabis-derived THC, as well as
hemp-derived CBD and other cannabinoids, to the United States, Brazil and other
major international markets.
The
permissions to export Pure Jamaican pharmaceutical products containing THC to
the U.S. were granted by Jamaica's Ministry of Health and Wellness (MOHW) to
Seven-10 Pharmaceuticals pursuant to valid corresponding import permits
received from the U.S. Drug Enforcement Administration (DEA). The products were
shipped to a DEA-licensed facility in the U.S. for successful analytical
testing.
Once
the DEA approves the rescheduling of THC from Schedule I to Schedule III
under the U.S. Controlled Substance Act, as is widely anticipated, Seven-10
intends to request DEA permits to ship Pure Jamaican pharmaceutical THC
products from Jamaica to patients in the U.S., subject to valid doctor
prescriptions and all relevant DEA, Food and Drug Administration (FDA) and
state pharmacy distribution regulations.
Meanwhile,
Seven-10 has already begun shipping Pure Jamaican's Botanicos
pharmaceutical tinctures with THC and other cannabinoids directly to patients
in Brazil, pursuant to ANVISA import permits. Together, Brazil and the U.S.
represent populations of more than 500 million people, providing tremendous
potential demand.
Scott
Cathcart, CEO of Pure Jamaican and Seven-10 Pharmaceuticals, said, "This
is a proud moment for Jamaica and for our group of companies. Jamaica has long
been associated with 'ganja' but never before in this context as a producer and
legal exporter of THC as a pharmaceutical-grade medicine. As the only company
in Jamaica licensed for pharmaceutical manufacturing of cannabinoids, we are
proud to be leading the way to elevating the role of Jamaica in the global
cannabis ecosystem."
The
President of Jamaica Promotions Corp. (JAMPRO), Shullette Cox, said that
"the growth of the cannabis industry for medicinal purposes has been a
priority of the government of Jamaica and particularly, the export of
value-added products from Jamaica. The success of Pure Jamaican and Seven-10
Pharmaceuticals is applauded as JAMPRO continues to facilitate the local
medicinal cannabis industry and ensuring its role in driving the growth of
exports."
Dr.
Ellen Campbell Grizzle, chief regulatory and compliance officer of Pure
Jamaican and Seven-10 Pharmaceuticals, and former dean of the College of Health
Sciences, UTech, said, "This is a labor of love and not easy. Jamaica has
52 percent of the world's medicinal plants in our small island nation, and we
are very proud to be exploring ways to identify new botanical medicines to
bring health, wellness, new exports and economic growth to our country."
